Companies › Allarity Therapeutics
1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| 2X-121 Poly [ADP-ribose] polymerase-1 inhibitor; Poly [ADP-ribose] polymerase 2 inhibitor; Tankyrase 1/2 inhibitor | PARP1, PARP2, TNKS2, TNKS | Phase 2 | Advanced Ovarian Cancer | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03878849 | 2X-121 | Phase 2 | Advanced Ovarian Cancer | Oncology | Mar 2027 |
Cash of $17m on 2026-06-30; operating cash outflow about $14m a year; runway about 14 months at that burn, to Sep 2027; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
AstraZeneca Merck & Co. (MSD) Pfizer Johnson & Johnson (Janssen) GSK Eikon Therapeutics BeiGene Impact Therapeutics pharmaand Boryung Pharmaceutical
VIVUS CNS Pharmaceuticals Impact Therapeutics Acrivon Therapeutics Dogwood Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.